Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?

Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of se...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerlach, Aaron C., Krajewski, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034102/
https://www.ncbi.nlm.nih.gov/pubmed/27713381
http://dx.doi.org/10.3390/ph3092884
_version_ 1782317931753897984
author Gerlach, Aaron C.
Krajewski, Jeffrey L.
author_facet Gerlach, Aaron C.
Krajewski, Jeffrey L.
author_sort Gerlach, Aaron C.
collection PubMed
description Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2(nd) and 3(rd) generation AEDs as well as compounds in development with novel mechanisms of action.
format Online
Article
Text
id pubmed-4034102
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40341022014-05-27 Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going? Gerlach, Aaron C. Krajewski, Jeffrey L. Pharmaceuticals (Basel) Review Current marketed antiepileptic drugs (AEDs) consist of a variety of structural classes with different mechanisms of action. These agents typically have non-overlapping efficacy and side-effect profiles presenting multiple treatment options for the patient population. However, approximately 30% of seizure sufferers fail to respond to current therapies often because poorly tolerated side-effects limit adequate dosing. The scope of this review is to summarize selected advances in 2(nd) and 3(rd) generation AEDs as well as compounds in development with novel mechanisms of action. MDPI 2010-09-01 /pmc/articles/PMC4034102/ /pubmed/27713381 http://dx.doi.org/10.3390/ph3092884 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Gerlach, Aaron C.
Krajewski, Jeffrey L.
Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title_full Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title_fullStr Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title_full_unstemmed Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title_short Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?
title_sort antiepileptic drug discovery and development: what have we learned and where are we going?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034102/
https://www.ncbi.nlm.nih.gov/pubmed/27713381
http://dx.doi.org/10.3390/ph3092884
work_keys_str_mv AT gerlachaaronc antiepilepticdrugdiscoveryanddevelopmentwhathavewelearnedandwherearewegoing
AT krajewskijeffreyl antiepilepticdrugdiscoveryanddevelopmentwhathavewelearnedandwherearewegoing

Ejemplares similares